Mycosis Fungoides (Cutaneous T-Cell Lymphoma)

Table of Contents

  1. Overview and Epidemiology
  2. Pathophysiology and Immunophenotype
  3. Clinical Stages (TNMB Staging)
  4. Diagnosis
  5. Treatment: Skin-Directed Therapies (Early Stage)
  6. Treatment: Systemic Therapies (Advanced Disease)
  7. Prognosis
  8. Quality of Life and Patient Guidance
  9. Key Research Papers
  10. Featured Videos
  11. Connections

Overview and Epidemiology

Mycosis fungoides (MF) is the most common primary cutaneous lymphoma, accounting for approximately 50% of all cutaneous lymphomas. Despite its alarming name — coined by French dermatologist Jean-Louis-Marc Alibert in 1806 after observing mushroom-shaped skin tumors — the disease follows a surprisingly indolent course in most patients, progressing over years to decades rather than months.

MF belongs to the broader category of cutaneous T-cell lymphomas (CTCL), a group of non-Hodgkin lymphomas arising from skin-homing T lymphocytes. The malignant cells are epidermotropic CD4+ T cells — they have an abnormal drive to enter and accumulate within the outer layers of the skin.

Key epidemiological facts:

Back to Table of Contents

Pathophysiology and Immunophenotype

The hallmark of MF is the clonal proliferation of mature, post-thymic CD4+ CD45RO+ memory T cells that have acquired an abnormal drive to home to the epidermis (epidermotropism). In normal immunity, these memory T cells patrol skin tissue; in MF, a clone of these cells accumulates, evades immune surveillance, and eventually transforms into frank lymphoma.

Immunophenotypic profile:

Clonal T-cell receptor (TCR) gene rearrangement is detectable by PCR in involved skin and, in advanced disease, in peripheral blood. Identifying the same clone in both skin and blood is central to diagnosing Sézary syndrome. Clonality alone does not establish malignancy — benign conditions can show oligoclonal or even apparently clonal expansions — but TCR clonality in the appropriate clinical and histological context strongly supports the diagnosis of MF.

The precise molecular initiating event is unknown. Candidate pathways include chronic antigen stimulation, JAK-STAT signaling dysregulation, loss of tumor suppressor function (CDKN2A deletion is common), and epigenetic silencing. Transformation to large-cell lymphoma (CD30+ or CD30–) can occur in advanced disease and carries a worse prognosis.

Back to Table of Contents

Clinical Stages (TNMB Staging)

MF is staged using the TNMB system — Tumor extent in skin (T), lymph Node involvement (N), visceral organ involvement (M), and Blood involvement (B). Understanding the clinical appearance at each stage is critical because early MF is notoriously difficult to distinguish from common benign skin conditions.

Patch Stage (Stage IA / IB)

Patches are flat, subtle, scaly erythematous lesions that are frequently misdiagnosed for years as eczema, psoriasis, tinea corporis, or contact dermatitis. Distinguishing features that should raise suspicion for MF include:

Most patients remain at the patch stage for many years to decades. Stage IA disease (patches covering less than 10% of body surface area) has a near-normal life expectancy with appropriate skin-directed treatment.

Plaque Stage (Stage IIA)

Plaques are thicker, raised, indurated lesions that develop superimposed on, or in place of, existing patches. They may be more intensely erythematous, more pruritic, and show more obvious scaling. At stage IIA, lymph nodes may be palpably enlarged (reactive adenopathy or early involvement), but lymph node biopsy shows only dermatopathic changes without frank lymphomatous involvement.

Tumor Stage (Stage IIB / III)

The tumor stage is defined by the emergence of raised, nodular tumors — the "mushroom-shaped projections" that gave the disease its name when Alibert first described it in 1806. Tumors may ulcerate and become secondarily infected. Prognosis worsens significantly at this stage. Stage III describes diffuse erythroderma without significant blood involvement.

Sézary Syndrome — Erythrodermic / Leukemic Variant (Stage IVA)

Sézary syndrome (SS) is the leukemic variant of CTCL and represents the most severe form of the disease. Diagnostic criteria require the triad of:

Additional features include severe, debilitating pruritus; fissuring of the palms and soles; ectropion (eyelid eversion); and total alopecia. Sézary syndrome carries a median survival of 2–4 years from diagnosis, making it the most challenging CTCL to manage.

Visceral Stage (Stage IVB)

Stage IVB involves spread to visceral organs — liver, lung, spleen, or bone marrow. This stage carries the worst prognosis and requires systemic chemotherapy approaches, with consideration of allogeneic stem cell transplantation in eligible patients.

Back to Table of Contents

Diagnosis

Diagnosis of MF is notoriously challenging and requires integration of clinical, histopathological, immunophenotypic, and molecular data. No single finding is diagnostic; the diagnosis is established by the overall pattern.

Skin Biopsy

Multiple biopsies from different lesions are strongly recommended — a single biopsy has limited sensitivity, and histological findings vary across lesions and over time. Key histological features include:

Immunohistochemistry (IHC)

IHC staining of biopsy material confirms the T-cell lineage and detects antigen loss: CD3+, CD4+, and importantly CD7– (loss) and variable CD5 loss. CD8+ variants exist but are uncommon.

T-Cell Receptor Gene Rearrangement (TCR PCR)

PCR amplification of the TCR gamma or beta gene detects a clonal T-cell population in skin and peripheral blood. Identical clones in both skin and blood support a diagnosis of Sézary syndrome. Clonality analysis is interpreted alongside clinical and histological findings.

Blood Studies

Staging Imaging

CT scan of chest, abdomen, and pelvis (or PET-CT in advanced disease) assesses lymph node and visceral involvement for accurate TNMB staging. Lymph node biopsy is performed when nodes are enlarged to distinguish reactive (dermatopathic) from malignant involvement.

Back to Table of Contents

Treatment: Skin-Directed Therapies (Early Stage)

For patients with stage IA and IB disease (patch and thin plaque stage), the standard approach is skin-directed therapy aimed at controlling symptoms and preventing progression, rather than cure. These treatments are applied to the skin and minimize systemic side effects.

Topical Corticosteroids

High-potency topical steroids are often the first-line treatment for limited patch-stage disease. They reduce inflammation and pruritus and can produce partial or complete remission of individual lesions. Long-term use carries the standard risks of topical steroid atrophy, particularly problematic given the thin skin already characteristic of poikilodermatous patches.

Topical Mechlorethamine (Nitrogen Mustard — Valchlor)

Mechlorethamine gel (Valchlor) is an FDA-approved topical alkylating agent for stages IA and IIA MF. It is applied daily to affected skin. Response rates of 60–70% have been reported. The main side effect is skin irritation and contact hypersensitivity. Previously available only as compounded ointments, the FDA-approved 0.02% gel formulation (Valchlor) standardized dosing.

Phototherapy

Total Skin Electron Beam Therapy (TSEBT)

TSEBT delivers low-energy electrons to the entire skin surface. Electrons penetrate only a few millimeters — deep enough to treat MF in the dermis and epidermis, but too shallow to cause significant internal organ exposure. It is highly effective for extensive patch and plaque disease and for early tumor-stage disease. TSEBT is available only at specialized academic centers with the required equipment and physics expertise. Responses are often durable, but MF commonly relapses after 2–3 years, and repeat courses are limited by cumulative skin toxicity.

Back to Table of Contents

Treatment: Systemic Therapies (Advanced Disease)

Advanced-stage MF (tumor stage, erythrodermic, Sézary syndrome, or visceral involvement) requires systemic therapy. Several agents are specifically FDA-approved for MF/CTCL; others are used off-label or in clinical trials. Conventional cytotoxic chemotherapy is generally avoided in early lines because it produces transient responses without survival benefit and causes significant immunosuppression.

Bexarotene (Targretin)

Bexarotene is an oral retinoid X receptor (RXR) agonist that modulates T-cell differentiation and proliferation. FDA-approved for CTCL, it achieves approximately 45% overall response in previously treated patients. The most significant and nearly universal side effect is severe hypertriglyceridemia, which requires concomitant lipid-lowering therapy (fenofibrate is preferred; statins are added if needed). Central hypothyroidism occurs in virtually all patients and requires thyroid hormone replacement. Teratogenic — strict contraception required.

Vorinostat (Zolinza)

Vorinostat was the first histone deacetylase (HDAC) inhibitor approved by the FDA (2006) for the treatment of CTCL in patients with progressive, persistent, or recurrent disease. It is taken orally. HDAC inhibitors work through epigenetic modification — they prevent the removal of acetyl groups from histone proteins, allowing genes involved in cell cycle arrest and apoptosis to remain accessible. Response rates in refractory CTCL are approximately 24–30%. Key side effects include fatigue, gastrointestinal symptoms, thrombocytopenia, and pulmonary embolism risk (requires monitoring).

Romidepsin (Istodax)

Romidepsin is an intravenous HDAC inhibitor (cyclic depsipeptide class) FDA-approved for CTCL and peripheral T-cell lymphoma. Given on days 1, 8, and 15 of a 28-day cycle, it achieves response rates of approximately 34–38% in refractory CTCL, with particularly good responses in Sézary syndrome. Side effects include nausea, fatigue, QTc prolongation (cardiac rhythm monitoring required), and cytopenias. Infection risk is significant.

Mogamulizumab (Poteligeo)

Mogamulizumab is a humanized anti-CCR4 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). CCR4 (CC-chemokine receptor 4) is highly expressed on malignant MF and Sézary cells, making it an excellent therapeutic target. FDA-approved in 2018 for previously treated MF and Sézary syndrome, it demonstrated superior progression-free survival vs. vorinostat (7.7 months vs. 3.1 months) in the landmark MAVORIC trial (Kim et al., 2018). Important considerations:

Extracorporeal Photopheresis (ECP)

ECP is a specialized immunotherapy procedure particularly effective for Sézary syndrome and erythrodermic MF. The process involves:

  1. Leukapheresis: white blood cells (mononuclear cells — MNCs) are separated from the patient's blood by an apheresis machine.
  2. Ex vivo photoactivation: the collected MNCs are exposed to 8-methoxypsoralen (8-MOP) and UVA irradiation outside the body (ex vivo).
  3. Reinfusion: the treated (partially killed/altered) cells are returned to the patient, where they appear to induce an immune response against the malignant T-cell clone.

ECP is typically performed on two consecutive days per month. It is well-tolerated with few systemic side effects. Response rates of 30–80% in erythrodermic CTCL are reported, with best responses in patients with lower Sézary cell burdens and shorter disease duration. ECP is frequently combined with other systemic agents (bexarotene, interferon-alpha) for enhanced response.

Allogeneic Stem Cell Transplantation (Allo-SCT)

Allo-SCT offers curative potential for advanced MF and Sézary syndrome, with sustained complete remissions reported in a subset of patients — likely driven by graft-versus-lymphoma (GVL) effect. However, it carries significant treatment-related mortality (TRM) from infection, GVHD, and organ toxicity, and is reserved for younger, fit patients with advanced refractory disease. Careful patient selection and timing (particularly avoiding mogamulizumab in the immediate pre-transplant period) are critical.

Back to Table of Contents

Prognosis

Prognosis in MF is strongly determined by disease stage at diagnosis. The reassuring reality for most patients — who present with early patch or plaque disease — is that survival is not substantially different from age-matched controls when disease remains at stage IA.

Adverse prognostic factors beyond stage include: elevated LDH, large-cell transformation, folliculotropic MF (a variant with follicular involvement that is more aggressive), and older age at diagnosis. Folliculotropic MF is staged and treated as if it were one stage higher than its skin involvement would suggest.

Back to Table of Contents

Quality of Life and Patient Guidance

Living with MF presents unique challenges — the combination of a chronic, incurable (at early stage), visible skin disease with a cancer diagnosis creates significant psychological burden. Key considerations:

The Pruritus Problem

Pruritus (itch) is often the most debilitating symptom, frequently described by patients as "maddening" and far more distressing than the visible appearance of lesions. Scratching damages already fragile skin, creates entry points for infection, and disrupts sleep. Treatments targeting itch specifically — including antihistamines (limited efficacy), gabapentin, aprepitant (NK1 receptor antagonist), and dupilumab (in select cases) — may provide relief. Importantly, treating the underlying MF effectively is the most reliable way to control pruritus.

Psychosocial Burden

The combination of a cancer diagnosis, chronic visible skin changes, severe itch, and prolonged diagnostic uncertainty (many patients receive incorrect diagnoses for years before MF is confirmed) is associated with high rates of anxiety and depression. Peer support groups — particularly those specifically for CTCL/MF — can provide community, information, and emotional support that general cancer support groups may not offer. The Cutaneous Lymphoma Foundation (CLF) maintains patient education resources and a patient registry.

Infection Risk

Disrupted skin barrier and immunosuppressive treatments significantly increase infection risk. Staphylococcus aureus colonization of MF skin lesions is nearly universal and can trigger flares; many dermatologists incorporate skin decolonization protocols (dilute bleach baths, mupirocin nasal ointment) into routine management. Patients should promptly report signs of skin infection — increased warmth, pain, purulent discharge, fever — for early treatment.

What to Ask Your Dermatologist

Clinical Trials

Given the rarity of MF and the limited curative options available outside of allogeneic transplant, participation in clinical trials is strongly encouraged for patients with advanced or refractory disease. Active trials can be identified at clinicaltrials.gov by searching "mycosis fungoides" or "cutaneous T-cell lymphoma."

Back to Table of Contents

Key Research Papers

  1. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90(1):354–371. PMID: 10570378
  2. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). J Clin Oncol. 2007;25(5):613–622. PMID: 15956130
  3. Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T-cell lymphoma. Lancet. 2009;374(9687):391–403. PMID: 19571797
  4. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204. PMID: 29040154
  5. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115. PMID: 17033959
  6. Piekarz RL, Frye AR, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417. PMID: 19177205
  7. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. J Am Acad Dermatol. 2005;52(4):597–604. PMID: 10728958
  8. Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1–37. PMID: 20131909
  9. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–4491. PMID: 17488960
  10. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39. PMID: 15569138
  11. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785. PMID: 24920551
  12. Jahan-Tigh RR, Vadlamudi G, Hastings J, et al. Flow cytometry in cutaneous T cell lymphomas. J Invest Dermatol. 2012;132(3 Pt 2):873–883. PMID: 28231090

Search PubMed for more: Mycosis fungoides treatment | Cutaneous T-cell lymphoma CTCL | Sézary syndrome

Back to Table of Contents

Back to Table of Contents

Connections

Back to Table of Contents